GYRE
Gyre Therapeutics Inc.
NASDAQ: GYRE · HEALTHCARE · BIOTECHNOLOGY
$7.68
+4.49% today
Updated 2026-04-30
Market cap
$696.73M
P/E ratio
381.50
P/S ratio
5.98x
EPS (TTM)
$0.02
Dividend yield
—
52W range
$7 – $12
Volume
0.1M
Gyre Therapeutics Inc. (GYRE) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$7.68
12-Month target
$0.94
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.2B | $0.2B | $0.2B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 20.00% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 4.31%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.